Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc (NASDAQ:ATOS), the biopharmaceutical company, has appointed Tessa Cigler, the breast cancer specialist, to its board of directors, effective immediately. Cigler works as a medical oncologist and clinical investigator at New York's Weill Cornell Breast Center, dealing with breast cancer patients daily.

Atossa Therapeutics adds breast cancer expert to board

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Tessa Cigler, M.D., M.P.H. was appointed to Atossa's board of directors, effective immediately. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Atossa Therapeutics Inc (NASDAQ:ATOS) announced it will present data from the 40mg pharmacokinetic run-in cohort of its ongoing Phase 2 EVANGELINE study at the American Association for Cancer Research Annual Meeting being held in San Diego, California, from April 5 to 10. The EVANGELINE study is evaluating Atossa's lead asset (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with estrogen receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.

Atossa Therapeutics to present data from ongoing Phase 2 breast cancer trial

Atossa Therapeutics Inc (NASDAQ:ATOS) announced that the first patient has been dosed with its proprietary selected estrogen receptor modulator (Z)-endoxifen in its Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS) Phase 2 study. DCIS is considered the earliest form of breast cancer, usually found during breast cancer screening.

Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trial

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS) study. RECAST DCIS is an ongoing Phase 2 platform study designed to offer women diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active surveillance without surgery.

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

Atossa Therapeutics Inc (NASDAQ:ATOS) shares have a 300% upside on the strength of the clinical-stage biopharmaceutical company's lead asset Z-endoxifen as a potential breast cancer treatment, according to analysts at H.C. Wainwright & Co.

Atossa Therapeutics' ‘standalone and superior drug' Z-endoxifen for breast cancer seen boosting shares by 300%

Atossa Therapeutics Inc (NASDAQ:ATOS) announced that it has fully enrolled the (Z)-endoxifen arm of its ongoing Phase 2 I-SPY 2 clinical trial targeting breast cancer.   The study is evaluating Atossa's selective estrogen receptor modulator (Z)-endoxifen as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive invasive breast cancer.

Atossa Therapeutics achieves patient enrollment milestone for Phase 2 breast cancer trial

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that the (Z)-endoxifen arm of the ongoing Phase 2 I-SPY 2 clinical trial has fully enrolled. In the study, (Z)-endoxifen, Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), is being evaluated as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer.

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

Sarepta Therapeutics

United Therapeutics

For many biotech stocks, price and performance hinges on the success of a drug in testing. This means most biotech companies rely on one market opportunity to succeed financially.

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market

Atossa Therapeutics Inc (NASDAQ:ATOS), a clinical stage biopharmaceutical company specializing in breast cancer treatments, outlined its progress over the past year in a letter to shareholders. The company reported notable progress in 2023, marked by four ongoing Phase 2 trials investigating their proprietary (Z)-endoxifen.

Atossa Therapeutics CEO dialogue between doctors and patients about breast density in 2024

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company's President and Chief Executive Officer:

Atossa Therapeutics Issues Letter to Shareholders

Atossa Therapeutics Inc (NASDAQ:ATOS) has appointed Dr. Arezoo Mirad as Senior Medical Director, the clinical biopharmaceutical company announced Monday.

Atossa Therapeutics taps Arezoo Mirad for Senior Medical Director

SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad as Senior Medical Director.

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that it has reached full enrollment in the Company's Karisma-Endoxifen clinical trial, the 240-person Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). Participants have been randomized to placebo, 1 mg, and 2 mg daily doses of (Z)-endoxifen and will be treated for six months, over the course of which mammograms are conducted to measure reduction in MBD. MBD change is used as a proxy for therapy response.

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics Inc (NASDAQ:ATOS) said during the third quarter it made significant advancements both as a company and across its proprietary oral formulation of (Z)-endoxifen research program. The breast cancer-focused biopharmaceutical company on Monday said it has four ongoing Phase 2 studies evaluating (Z)-endoxifen, having achieved 80% enrolment in its Karisma and I-SPY trials.

Atossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3Q

SEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended September 30, 2023, and provides an update on recent company developments.

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Inc (NASDAQ:ATOS) announced it has appointed Jonathan Finn to its board of directors, effective November 8, 2023. The company noted that Finn has more than 25 years of experience in the financial sector with a focus on mid-stage biotechnology and technology companies, currently serving as Executive Vice President and Chief Investment Officer at Vantage Consulting Group.

Atossa Therapeutics adds experienced finance exec to board of directors

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Jonathan Finn, CFA, has been appointed to Atossa's board of directors, effective November 8, 2023. Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology companies.

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing the progression of ductal carcinoma in situ (DCIS), the presence of abnormal cells inside a milk duct in the breast, to breast cancer.  The Phase 2 platform study, titled “Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS),” has been initiated by Quantum Leap Healthcare Collaborative (QLHC), a charitable organization established in 2005 as a collaboration between medical researchers at the University of California, San Francisco and Silicon Valley entrepreneurs.

Atossa Therapeutics' (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery SAN FRANCISCO , Oct. 30, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, a selective estrogen receptor modulator (SERM) in development by Atossa Therapeutics (Nasdaq: ATOS); HAVAH T+Ai™, a proprietary combination of testosterone (T) and anastrozole (Ai) that targets the androgen and estrogen receptor pathways in development by Havah Therapeutics; and ORSERDU® (elacestrant), the only FDA approved oral selective estrogen receptor degrader (oSERD) in development by Stemline Therapeutics Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group.

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Dr. Steven Quay calls for nutritional guidelines for adolescent girls to reduce future breast cancer SEATTLE , Oct. 11, 2023 /PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD is calling for nutritional guidelines for adolescent girls to reduce processed and fast-food consumption during puberty to prevent future breast cancer. His recommendation is based on recent research showing a link between consumption of a particular set of chemicals produced by the high temperatures used to fry or grill foods that have a high level of sugars and the induction of pre-cancerous changes during pubertal breast development.

Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

SEATTLE, WA / ACCESSWIRE / September 18, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge factor.

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight' rating and a $5 price target on their belief that positive trial data readouts for Atossa's investigational breast cancer drug will drive upward earnings estimate revisions and send the firm's stock higher. Atossa's shares traded up on Friday morning, adding 11.5% to US$0.83.

Atossa Therapeutics' upcoming breast cancer trial results expected to drive stock higher

Atossa Therapeutics Inc (NASDAQ:ATOS) is targeting three different stages of the breast cancer continuum with its proprietary oral form of Endoxifen, a drug that combines estrogen receptor degradation, suppression, and protein kinase C (PKC) beta inhibition. Atossa CEO Dr.

News for Atossa Genetics Stock (ATOS)